BBHC
ORMP icon

Brown Brothers Harriman & Co’s Oramed Pharmaceuticals ORMP Stock Holding History

Brown Brothers Harriman & Co’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8
Closed -$18 – 1234
2023
Q4 		$18 Hold
8
– – ﹤0.01% 1145
2023
Q3 		$21 Hold
8
– – ﹤0.01% 1209
2023
Q2 		$29 Hold
8
– – ﹤0.01% 1213
2023
Q1 		$17 Hold
8
– – ﹤0.01% 1257
2022
Q4 		$96 Hold
8
– – ﹤0.01% 1224
2022
Q3 		$0 Hold
8
– – ﹤0.01% 1564
2022
Q2 		$0 Buy
+8
New +$43 ﹤0.01% 1382

Other funds holding ORMP

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Brown Brothers Harriman & Co's ORMP Position: Q1 2024 in Review

Brown Brothers Harriman & Co sold out of Oramed Pharmaceuticals (ORMP) in Q1 2024, closing a stake of 8 shares — an estimated $18 sold.

Brown Brothers Harriman & Co first reported a position in ORMP in Q2 2022 and held it in 7 quarters. The position peaked at $96 in Q4 2022. 51 funds tracked by Wall St. Rank hold ORMP as of Q1 2024.

  • Brown Brothers Harriman & Co reported no remaining Oramed Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 8 Oramed Pharmaceuticals shares in Q1 2024, an estimated $18.
  • Brown Brothers Harriman & Co first reported a position in Oramed Pharmaceuticals in Q2 2022 and held it in 7 quarters.
  • Brown Brothers Harriman & Co's Oramed Pharmaceuticals position peaked at $96 in Q4 2022.
  • 51 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2024.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2024, filed 10 May 2024.